Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
复制标题
DOI：
--
复制
发表时间：
2011-02
影响因子：
2
通讯作者：
T. Nagata;C. Sakakura;S. Komiyama;A. Miyashita;M. Nishio;Y. Murayama;S. Komatsu;A. Shiozaki;Y. Kuriu;H. Ikoma;M. Nakanishi;D. Ichikawa;H. Fujiwara;K. Okamoto;T. Ochiai;Y. Kokuba;T. Sonoyama;E. Otsuji
中科院分区：
文献类型：
--
作者：
T. Nagata;C. Sakakura;S. Komiyama;A. Miyashita;M. Nishio;Y. Murayama;S. Komatsu;A. Shiozaki;Y. Kuriu;H. Ikoma;M. Nakanishi;D. Ichikawa;H. Fujiwara;K. Okamoto;T. Ochiai;Y. Kokuba;T. Sonoyama;E. Otsuji
背景最近的发现表明，具有表面CD标记的细胞包括可产生癌症簇的癌症干细胞（CSC），并且CSC的存在可能与预后相关。CD133和CD44是鉴定结肠直肠CSC最有用的标志物之一。材料与方法采用局部复发或非复发的临床病理病例的组织进行CD 133和CD 44的免疫组织学分析。结果复发组和未复发组的CD133阳性率分别为59.23%和38.7%，CD44阳性率分别为44.4%和35.5%。CD标记物的表达与其他临床病理因素无关。两种标志物均阳性的患者预后明显差于其他患者。结论CD133和CD44的检测可为大肠癌治疗方案的选择和加强随访提供有用的信息。
BACKGROUND Recent findings suggest that cells with surface CD markers include cancer stem cells (CSCs) which can produce a cancer cluster, and that the presence of CSCs may be linked with prognosis. CD133 and CD44 are among the most useful markers for identification of colorectal CSCs. MATERIALS AND METHODS An immunohistological analysis of CD133 and CD44 was performed using tissue from cases shown to be locoregionally recurrent or non-recurrent clinico-pathologically. RESULTS The CD133-positive rates were 38.7% and 59.23% in non-recurrent and recurrent cases, respectively, and the CD44-positive rates were 35.5% and 44.4%, respectively. Expression of the CD markers had no correlation with other clinicopathological factors. The prognosis of patients who were positive for both markers was significantly worse than that of other patients. CONCLUSION These results suggest that detection of CD133 and CD44 can provide useful information for selection of treatment and performance of intensive follow-up of colorectal cancer.